Gene · 1902
Papers2,112
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,112
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Diabetes and calcific aortic valve disease: controversy of clinical outcomes in diabetes after aortic valve replacement. | Front Endocrinol (Lausanne) | 2025 | 40810069 | PubTator, text mining | PubMed |
| Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseases. | Autoimmun Rev | 2025 | 40769405 | PubTator, text mining | PubMed |
| MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer. | Breast Cancer Res | 2025 | 40696387 | PubTator, text mining | PubMed |
| Microarray and Single-Cell RNA Sequencing Reveals G-Protein Gene Expression Signatures of Spermatogonia Stem Cell. | Stem Cell Rev Rep | 2025 | 40694278 | PubTator, text mining | PubMed |
| Multi-omics characterization of prognostic signature and novel molecular subtypes associated with anoikis and in vitro validation of CDKN2A in thyroid carcinoma. | Phytomedicine | 2025 | 40527061 | PubTator, text mining | PubMed |
| Can a novel lysophosphatidic acid receptor 1 antagonist ACT in time to halt pulmonary fibrosis and improve breathing? | J Pharmacol Exp Ther | 2025 | 40479885 | PubTator, text mining | PubMed |
| Effect of Corticosterone on Gene Expression in the Context of Global Hippocampal Transcription. | Int J Mol Sci | 2025 | 40430058 | PubTator, text mining | PubMed |
| Lysophosphatidic acid (LPA) receptor signaling enhances malignant potential in highly migratory lung cancer cells under hypoxic conditions. | Acta Histochem | 2025 | 40412000 | PubTator, text mining | PubMed |
| RETRACTION: Long Noncoding RNA ZFAS1 Promotes Tumorigenesis and Metastasis in Nasopharyngeal Carcinoma by Sponging Mir-892b to Up-Regulate LPAR1 Expression. | J Cell Mol Med | 2025 | 40346764 | PubTator, text mining | PubMed |
| Lysophosphatidic acid (LPA) receptor signaling modulates cellular functions of colon cancer cells under cobalt chloride-induced hypoxic conditions. | Adv Biol Regul | 2025 | 40345063 | PubTator, text mining | PubMed |
| Erratum to "A novel lysophosphatidic acid receptor 1 antagonist with high brain penetrability has a curative effect in the empathic pain-related fibromyalgia model" [J Pharmacol Sci (2025) 139-142]. | J Pharmacol Sci | 2025 | 40335367 | PubTator, text mining | PubMed |
| A novel lysophosphatidic acid receptor 1 antagonist with high brain penetrability has a curative effect in the empathic pain-related fibromyalgia model. | J Pharmacol Sci | 2025 | 40288824 | PubTator, text mining | PubMed |
| Benchmarking of germline copy number variant callers from whole genome sequencing data for clinical applications. | Bioinform Adv | 2025 | 40248358 | PubTator, text mining | PubMed |
| Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis. | Chest | 2025 | 40210090 | PubTator, text mining | PubMed |
| Targeting Autotaxin with imidazole- and Triazolyl-based inhibitors: Biological insights from in vitro and in vivo studies in pulmonary fibrosis. | Bioorg Chem | 2025 | 40199012 | PubTator, text mining | PubMed |
| The regulatory role of ZFAS1/miRNAs/mRNAs axis in cancer: a systematic review. | Oncol Res | 2025 | 40109869 | PubTator, text mining | PubMed |
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis. | J Pharmacol Exp Ther | 2025 | 40073729 | PubTator, text mining | PubMed |
| Analysis of cellular senescence-related genes in calcified aortic valve disease and the potential therapeutic role of β-Carotene. | PLoS One | 2025 | 40063555 | PubTator, text mining | PubMed |
| Promoted Translocation of Perfluorooctanoic Acid across the Blood-Retinal Barrier due to its Inhibition of Tight Junction Assembly by Antagonizing LPAR1. | Environ Sci Technol | 2025 | 40038073 | PubTator, text mining | PubMed |
| Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis. | J Med Chem | 2025 | 39909836 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1902/papers?page=4